1515
Abliva to participate in World Mitochondrial Disease Week 2021

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announces that the company will participate in World Mitochondrial Disease Week through videos that will be released on Abliva’s website daily during the week, 19 – 25 September.

The videos will be focused on increasing the understanding of the community to rare disease development, and more specifically to the development of new therapies for primary mitochondrial diseases (PMDs). Over the week we will highlight the huge unmet medical need in the area and discuss Abliva’s own efforts to treat mitochondrial disease patients with our two clinical stage compounds.

Starting 19 September, Abliva’s videos will be posted daily on https://abliva.com/poster/presentationer/world-mitochondrial-disease-week-2021/ as well as on the company’s YouTube channel and LinkedIn page.

World Mitochondrial Disease Week is an initiative of International Mito Patients (IMP). The purpose of the World Mitochondrial Disease Week is to raise awareness of mitochondrial disease (mito) on a global scale through educational, fundraising and advocacy activities.
https://mitochondrialdiseaseweek.org

Source: MFN
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

  • Full tillgång till di.se med nyheter och analyser

  • Tillgång till över 1100 aktiekurser i realtid

  • Dagens industri som e-tidning redan kvällen innan

  • Innehållet i alla Di:s appar, tjänster och nyhetsbrev

3 månader för
197 kr
Spara 1000 kr

Prenumerera

Redan prenumerant?